|
1) Dries DL, Exner DV, Gersh BJ, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1998; 32: 695-703
|
|
|
|
2) Hamaguchi S, Yokoshiki H, Kinugawa S, et al; Japanese Cardiac Registry of Heart Failure in Cardiology Investigators. Effects of atrial fibrillation on long-term outcomes in patients hospitalized for heart failure in Japan: a report from the Japanese Cardiac Registry of Heart Failure in Cardiology(JCARE-CARD). Circ J. 2009; 73: 2084-90
|
|
|
|
|
3) Rivero-Ayerza M, Scholte Op Reimer W, Lenzen M, et al. New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure Survey. Eur Heart J. 2008; 29: 1618-24
|
|
|
|
|
|
4) Wang TJ, Larson MG, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003; 107: 2920-5
|
|
|
|
|
|
5) Roy D, Talajic M, Nattel S, et al; Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008; 358: 2667-77
|
|
|
|
|
|
6) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J. 2008; 29: 2388-442
|
|
|
|
|
|
7) 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. Circulation. 2009; 119: e391-479
|
|
|
|
|
|
8) 不整脈薬物治療に関するガイドライン(2009年改訂版). 日本循環器学会HPオンライン
|
|
|
|
|
|
9) Yamashita T, Ogawa S, Sato T, et al and the J-BAF Investigators. Dose-response effects of bepridil in patients with persistent atrial fibrillation monitored with transtelephonic electrocardiograms. Circ J. 2009; 73: 1020-7
|
|
|
|
|
10) Aizawa Y, Kohsaka S, Suzuki S, et al and J- RHYTHM Investigators. Comparison of anti-arrhythmics used in patients with paroxysmal atrial fibrillation. Circ J. 2010; 74: 71-6
|
|
|
|
|
|
11) Hsu LF, Jaïs P, Sanders P, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med. 2004; 351: 2373-83
|
|
|
|
|
|
12) Marrouche NF, Brachmann J; CASTLE-AF Steering Committee. Catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation(CASTLE-AF)- study design. Pacing Clin Electrophysiol. 2009; 32: 987-94
|
|
|
|
|
|
13) Gasparini M, Auricchio A, Regoli F, et al. Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation. J Am Coll Cardiol. 2006; 48: 734-43
|
|
|
|
|
|
14) Gasparini M AA, Marco M, Regoli F, et al. For the MultiCenter Longitudinal Group. Long-term survival in patients undergoing cardiac resynchronization therapy: The importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. Eur Heart J. 2008: 29; 1644-52
|
|
|
|
|
|
15) Dickstein K, Bogale N, Priori S, et al; Scientific Committee; National Coordinators. The European cardiac resynchronization therapy survey. Eur Heart J. 2009; 3020: 2450-60
|
|
|
|
|
|
16) Khan MN, Jaïs P, Cummings J, et al; PABA-CHF Investigators. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med. 2008; 359: 1778-85
|
|
|
|
|